Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor.

Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling. Arthritis Res Ther (2017) 0.75

IgG Fc receptors. Annu Rev Immunol (2001) 8.63

Single step separation of human T and B cells using AET treated srbc rosettes. J Immunol Methods (1976) 3.41

A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature (1994) 2.11

Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood (2013) 1.78

The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol (2005) 1.63

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61

B cell selection and susceptibility to autoimmunity. J Immunol (2005) 1.46

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis (2007) 1.36

CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem (2001) 1.30

CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux. J Biol Chem (2000) 1.24

Inhibitory signaling by B cell Fc gamma RIIb. Curr Opin Immunol (1998) 1.05

B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther (2010) 1.04

Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther (2006) 1.01

Role of inhibitory BCR co-receptors in immunity. Infect Disord Drug Targets (2012) 1.00

Grb2 regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca2+ signalling. EMBO J (2011) 1.00

Grb2, a simple adapter with complex roles in lymphocyte development, function, and signaling. Immunol Rev (2009) 0.97

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum (2013) 0.93

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood (2007) 0.93

Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum (2010) 0.92

CD22 and autoimmune disease. Int Rev Immunol (2012) 0.88

Two distinct tyrosine-based motifs enable the inhibitory receptor FcgammaRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap. J Biol Chem (2004) 0.88

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmun Rev (2015) 0.85

Fc gamma receptor IIb modulates the molecular Grb2 interaction network in activated B cells. Cell Signal (2011) 0.84

Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells. Arthritis Rheumatol (2016) 0.83

Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. Arthritis Res Ther (2015) 0.82

Antigen receptor signaling competence and the determination of B cell fate in B-lymphopoiesis. Histol Histopathol (2005) 0.78